Comparison to NEU is purely on credibility of financials:
1. NEU credible FDA approved company sold its ticket for potential net share of revenue of usd30 to 50mln p.a. for 100mln usd upfront fee.
2. In BOT 300 000 prescriptions which is 1% of the market gives us USD 210mln Revenue( GP margin approx 80%) and more then 50mln USD p.a.net profit..on financials we should be better then NEU
very close to be credible ( FDA approval) and Japan sales supports our credentials
Both companies have Ph2 and Ph3 credible pipeline..
BOT - Anything but charting, page-6986
-
- There are more pages in this discussion • 2,286 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |